AN ANALYSIS OF THE DRUG GLEEVEC (imanitib mesylate)
This study is an analysis in one of the best discoveries that has significantly contributed to the treatment of Chronic Myeloid Leukemia (C.M.I.) (Dreifus D 4). This is cancer which starts form inside the bone marrow (Soft tissues that help form blood cells inside bones). The disease occurrence to both adults and children is common. Statistically, it affects 1-2 people/ 100 000 and makes approximately 7-20% of leukemia cases.
Likely trigger of this chromosomal abnormality has been cited as exposure to significant ionization radiation such as from a nuclear source or from previous exposure to other radiation sources, for instance, during medical diagnosis.